Abbreviations: IL-6: interleukin-6; NO: nitric oxide; LDL-C: low-density lipoprotein-cholesterol; TC: total cholesterol; VLDL: very low-density lipoprotein-cholesterol; HMG-CaA: 3-hydroxy-3-methylglutaryl coenzyme A; FPP: farnesylpyrophosphate; GGPP: geranylgeranylpyrophosphate.
Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other molecules of the same class, it shows high efficacy in the improvement of lipid profile, and, thanks to its non-cholesterol-lowering actions (anti-inflammatory, antioxidant and antithrombotic), represents a crucial tool for cardiovascular primary and secondary prevention.
Moreover, recent data highlight rosuvastatin beneficial effects in several other fields. In this manuscript we analyzed literature sources in order to better define rosuvastatin features and discuss some critical issues.